Portal vein thrombosis medical therapy

Portal vein thrombosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Portal vein thrombosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Portal vein thrombosis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Portal vein thrombosis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Portal vein thrombosis medical therapy
CDC on Portal vein thrombosis medical therapy
Portal vein thrombosis medical therapy in the news
Blogs on Portal vein thrombosis medical therapy
Directions to Hospitals Treating Portal vein thrombosis
Risk calculators and risk factors for Portal vein thrombosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

• Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
• Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
• Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
• Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Disease Name

• 1. Portal vein thrombosis with cirrhosis
  • NOTE: Chronic anticoagulation is generally not recommended

• 2. Portal vein thrombosis without cirrhosis
  • 2.1 Chronic portal vein thrombosis
    • 2.1.1 Chronic portal vein thrombosis with hypercoagulable state or previous history of vascular disease
      • 2.1.1.1 Long term anticoaugulation
        • Preferred regimen: Warfarin 2-5 mg PO q24h
      • 2.1.1.2 Treatment of esophageal varices
    • 2.1.2. Chronic portal vein thrombosis without hypercoagulable state or previous history of vascular disease
  • NOTE: Chronic anticoagulation is generally not recommended
    • 2.1.2.1 Treatment of esophageal varices
  • 2.2 Acute portal vein thrombosis
  • 2.1 Acute portal vein thrombosis with hypercoagulable state
    • Preferred regimen: Warfarin 2-5 mg PO q24h for long term
  • 2.2 Acute portal vein thrombosis without hypercoagulable state
    • Preferred regimen: Warfarin 2-5 mg PO q24h for 3-6 months